Summit Therapeutics PLC appointed David Roblin COO and president of research and development.

Roblin will lead research and development and commercial functions to support the development of the company's Duchenne muscular dystrophy and C. difficile infection programs. Roblin, who has been acting as a research and development adviser to Summit since 2014, will assume his new role on an interim basis in April, and become permanent in June.

He was most recently COO and director of scientific translation at the Francis Crick Institute, a London-based biomedical institute.